QTTB backs Phase II bempikibart results for Phase III move
Positive Phase II data for bempikibart in alopecia areata, with JAK-like efficacy and a strong safety profile, support plans to advance to Phase III and explore additional indications.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.